Home  |  Contact

Cellosaurus NCI-ADR-RES (CVCL_1452)

Cell line name NCI-ADR-RES
Synonyms NCI/ADR-RES; NCIADR.RES; NCI/ADRRES; NCIADRRES; ADR-RES; MCF-7/ADR; MCF-7/ADR-RES; MCF-7/AdrR; MCF-7/Adr; MCF-7/adr; MCF-7ADR; MCF7ADR; OVCAR-8/ADR; OVCAR8/ADR
Accession CVCL_1452
Secondary accession CVCL_0414; CVCL_3942
Resource Identification Initiative To cite this cell line use: NCI-ADR-RES (RRID:CVCL_1452)
Comments Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=20143388).
Part of: NCI-60 cancer cell line panel.
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00234.
Doubling time: 34 hours (NCI-DTP).
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep proteome analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Heterozygous for ERBB2 p.Gly776Val (c.2237G>T) (PubMed=17088437).
TP53 p.Tyr126_Lys132del (c.376_396del21) (from parent cell line).
HLA typing Source: PubMed=15748285
Class I
HLA-AA*01:01:01,25:01
HLA-BB*57:01:01
HLA-CC*06:02
Class II
HLA-DPDPB1*02:01:02,13:01
HLA-DQDQB1*03:03:02,06:02
HLA-DRDRB1*07:01,15:01:01
Disease High grade ovarian serous adenocarcinoma (NCIt: C105555)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1629 (OVCAR-8)
Sex of cell Female
Age at sampling 64Y
Category Cancer cell line
STR profile Source(s): DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=19372543

Markers:
AmelogeninX
CSF1PO11
D13S31712
D16S53913
D18S5114
D19S43314,16
D21S1128
D2S133819,23
D3S135818
D5S81812
D7S82012
D8S117910
FGA20
TH017
TPOX8
vWA16,17
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://dtp.cancer.gov/discovery_development/nci-60/nci-adrres.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=28
http://iclac.org/wp-content/uploads/Cross-Contaminations_v9_distribution.xlsx
Publications

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=9625176; DOI=10.1093/jnci/90.11.862
Scudiero D.A., Monks A., Sausville E.A.
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
J. Natl. Cancer Inst. 90:862-862(1998)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11-11(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=16504380; DOI=10.1016/j.canlet.2006.01.013
Liscovitch M., Ravid D.
A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells.
Cancer Lett. 245:350-352(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

DOI=10.4172/2157-7145.S2-005
Fang R., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21116879; DOI=10.1007/s12032-010-9747-1
Ke W., Yu P., Wang J., Wang R., Guo C., Zhou L., Li C., Li K.
MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research.
Med. Oncol. 28:S135-S141(2011)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

Cross-references
Cell line collections NCI-DTP; NCI/ADRRES
Cell line databases/resources SKY/M-FISH/CGH; 2897
Ontologies BTO; BTO:0004181
MCCL; MCC:0000310
Biological sample resources BioSample; SAMN03151880
BioSample; SAMN03151881
Chemistry resources ChEMBL-Cells; CHEMBL3308057
ChEMBL-Targets; CHEMBL613829
Gene expression databases GEO; GSM2099
GEO; GSM50197
GEO; GSM50260
GEO; GSM750832
GEO; GSM799367
GEO; GSM799430
GEO; GSM847073
GEO; GSM844614
GEO; GSM844615
GEO; GSM1153433
GEO; GSM1181271
GEO; GSM1181300
GEO; GSM2124672
Other Wikidata; Q54907717
Polymorphism and mutation databases Cosmic; 687498
Cosmic; 897420
Cosmic; 905987
Cosmic; 974233
Cosmic; 1044218
Cosmic; 1092617
Cosmic; 1312358
Cosmic; 1998459
Proteomic databases PRIDE; PXD005942